One molecule’s journey from discovery to market
With the help of outsourcing partners, the small biotech firm Nabriva brought lefamulin to patients by itself. Now it needs to make a profit in the tough-to-crack antibiotic business
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
June 22, 2020 Cover
Volume 98, Issue 24
With the help of outsourcing partners, the small biotech firm Nabriva brought lefamulin to patients by itself. Now it needs to make a profit in the tough-to-crack antibiotic business
With the help of outsourcing partners, the small biotech firm Nabriva brought lefamulin to patients by itself. Now it needs to make a profit in the tough-to-crack antibiotic business
Vanadium dioxide and samarium nickel oxide transform from insulators to metals and back when triggered by heat, light, or other stimuli
COVID-19 has meant a shift in plastics markets, and polymer makers are hustling to keep up
She is ‘bullish’ on the board’s future despite history of turmoil
Managing expectations will be key, says Jen Heemstra
The inexpensive, well-studied steroid could give doctors another tool in the coronavirus pandemic